MYLAN 2035 MYLAN 2035 Pill - pink capsule/oblong
Pill with imprint MYLAN 2035 MYLAN 2035 is Pink, Capsule/Oblong and has been identified as Topiramate (Sprinkle) 15 mg. It is supplied by Mylan Pharmaceuticals Inc.
Topiramate is used in the treatment of Migraine Prevention; Lennox-Gastaut Syndrome; Seizure Prevention; Epilepsy; Seizures and belongs to the drug class carbonic anhydrase inhibitor anticonvulsants. There is positive evidence of human fetal risk during pregnancy. Topiramate 15 mg is not a controlled substance under the Controlled Substances Act (CSA).
Images for MYLAN 2035 MYLAN 2035
Topiramate (Sprinkle)
- Imprint
- MYLAN 2035 MYLAN 2035
- Strength
- 15 mg
- Color
- Pink
- Shape
- Capsule/Oblong
- Availability
- Prescription only
- Drug Class
- Carbonic anhydrase inhibitor anticonvulsants
- Pregnancy Category
- D - Positive evidence of risk
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Mylan Pharmaceuticals Inc.
- National Drug Code (NDC)
- 00378-2035 (Discontinued)
More about topiramate
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (1,332)
- Drug images
- Side effects
- Dosage information
- Patient tips
- During pregnancy
- Support group
- Drug class: carbonic anhydrase inhibitor anticonvulsants
- Breastfeeding
Patient resources
- Topiramate drug information
- Topiramate Extended-Release Capsules
- Topiramate Extended-Release Sprinkle Capsules
- Topiramate Sprinkle Capsules
Other brands
Topamax, Trokendi XR, Eprontia, Topiragen, Qudexy XR
Professional resources
- Topiramate monograph
- Topiramate (FDA)
- Topiramate Capsules (FDA)
- Topiramate ER Capsules (FDA)
- Topiramate Tablets (FDA)
Other brands
Topamax, Trokendi XR, Eprontia, Qudexy XR
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.